The German Federal Ministry of Education and Research (BMBF), has transferred €2.45m to a research collaborative known as LeukoSyStem to “get to the root of the problem” of leukemia. With an emphasis on stem cell research and “the starting point of leukemia,” the collaborative involves prominent research groups within Germany, including scientists at Heidelberg University Hospital (UKHD), the Heidelberg Institute for Stem Cell Technology and Experimental Medicine at the German Cancer Research Center (HI-STEM/DKFZ), the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL).
Leukemia stem cells are thought to be the starting point of leukemia. Hence, the ability to eliminate them is an underlying premise for successful long-term therapy. This team will investigate the cells that are the origin of acute myeloid leukemia (AML) with the hopes of generating a greater understanding of how to ultimately develop cell therapy-based treatments.
The team will collect patient samples, in the form of isolated single cells, at various locations and investigate characteristic markers, mutations, functional data, and metabolic pathways all to...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).